酸涂层纳米颗粒用于药物输送:我们现在在哪里?
1Advanced Materials and Nanobiotechnology Laboratory, TardigradeNano LLC, Irvine, CA, USA.
Expert opinion on drug delivery
|December 8, 2024
概括
酸 (CaPs) 正在被探索为纳米颗粒的涂层,以提高药物输送. 本综述检查了CaP涂层纳米粒子,突出了它们克服以前限制和改善治疗应用的潜力.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 酸 (CaPs) 曾经是生物材料研究的主要焦点,但自20世纪90年代中期以来,人们对其的兴趣已经下降.
- 现在,CAP正在重新考虑作为复合结构的表面涂层,以增强其性能.
- 这种方法旨在减轻单个组件的弱点,并改善与生物系统的相互作用.
研究的目的:
- 审查用于药物输送的CaP涂层纳米颗粒的历史发展和当前状态.
- 分析最近的例子,挑战和未来在这个领域的机会.
- 通过文献分析,提供一个时间的角度.
主要方法:
- 文献学分析 文献学分析
- 建造时间表 时间表 建造时间表
- 关于CaP涂层纳米粒子现有文献的综述.
主要成果:
- 纳米颗粒上的CaP涂层可以增加生物活性并促进细胞吸收.
- 这些混合结构为智能药物输送提供pH敏感性质.
- 使用CaP涂层是一种可行的策略,可以振兴人们对酸盐的兴趣.
结论:
- 使用CaP涂层的复合结构显示出高级应用的巨大潜力.
- 对CaP涂层纳米颗粒的持续探索对于未来药物输送方面的创新至关重要.
- 预计这些混合材料将在生物医学应用中产生新的特性和功能.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


